Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Luxembourg

Marie Skłodowska-Curie Action · Running

LINK-M Investigating the Interplay of Natural Killer Cells and Microbiome in Non-Hodgkin's Lymphoma

Coordinator
Luxembourg Institute of Health, Luxembourg
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€216k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101209208

What the project is doing

In the project's own words, from its summary on CORDIS.

Natural Killer (NK) cells have a critical role in anti-cancer immunity and recently the influence of the microbiome in cancer immunotherapy was shown. Comprehending the complex interplay between the expression of NK cells ligands involved in immune evasion mechanisms and the microbiome is crucial for achieving immunotherapy success. Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) are two types of Non-Hodgkin Lymphomas (NHL) characterized by accumulating B lymphocytes in lymph nodes, and extranodal sites.

DLBCL and FL usually show aggressive and indolent behavior respectively. DLBCL, includes the known subtypes germinal center B-cells (GCB) and activated B-cells (ABC), and, like the DLBCL-GCB subtype, FL have a germinal origin as well. The mechanism involved in the immune-microbiome interplay are not clearly understood, hampering the improvement of therapeutic possibilities. The objective of this study is to reveal the complex interplay between the NK cells and the microbiome in DLBCL and FL patients and harness its therapeutic potential.

To achieve this, I will use single-cell RNA sequencing and flow cytometry to analyze the composition of NK cells dissociated from DLBCL and FL samples. Then, I will use correlative analyses to identify the NK ligands/receptors that are more expressed in patients with low diversity and high variability microbiome. Ultimately, I will address the impact of this correlation in the response to immunotherapy. The results will pave the way for patient risk stratification establishment and new treatment options approaches.

Conducting this project at the Tumor Stroma Interactions (TSI) group will provide me a solid scientific basis as well as technical development for further progressing my scientific career.

Topics

Who is involved

OrganisationCityCountryRole
Luxembourg Institute of HealthStrassenLuxembourgCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI